With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Compounded semaglutide has not gone through the same review process as FDA-approved drugs, so it is unclear how safe or effective these products are. It’s important to get a prescription for ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Semaglutide was initially approved under the brand name Ozempic for Type 2 diabetes, while the brand name Wegovy is only approved for weight loss. Here, we’ll compare tirzepatide (Zepbound ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US.

Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes. 1 Obesity directly leads to ...